Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral acromegaly drug candidate, Palsonify (paltusotine), showing sustained biochemical control and symptom relief across two Phase 3 studies.

At the ENDO 2025 conference, Crinetics shared new data from its ongoing PATHFNDR-1 and PATHFNDR-2 studies, showing that patients who switched from monthly injections to once-daily oral Palsonify were able to keep their insulin-like growth factor 1 (IGF-1) and growth hormone levels steady for nearly two years. 

Symptom scores, based on the acromegaly symptom diary (ASD), also remained stable. Palsonify was generally well tolerated.

In PATHFNDR-2, which studied patients with uncontrolled acromegaly, Palsonify led to sustained reductions in IGF-1 and symptom flares through 84 weeks. 

Notably, patients who had previously been on placebo experienced meaningful improvements after switching to Palsonify in the open-label extension (OLE).

A pooled analysis of symptom scores across both studies showed a significant decrease in day-to-day symptom flares for patients switching from injectables from over 30% of days on somatostatin receptor ligand (SRL) to just 6.2% during stable Palsonify dosing, regardless of baseline control or treatment history.

CEO Scott Struthers said the data reinforce Palsonify’s potential as a once-daily, next-generation treatment for acromegaly. 

Crinetics is also advancing Palsonify in a Phase 3 trial for carcinoid syndrome in patients with neuroendocrine tumors, following promising Phase 2 results in flushing and bowel movement control.

In March, the European Medicines Agency (EMA) validated Crinetics' marketing authorization application (MAA) for Palsonify as a long-term maintenance therapy for acromegaly. 

The EMA had previously granted the drug Orphan Drug Designation in February. 

On Stocktwits, retail sentiment for Crinetics was ‘bullish’ amid ‘high’ message volume.

Crinetics’ stock has declined 38.1% so far in 2025.

See also: Trump’s 35% Tariff Threat Ripples Through Walmart’s Bangladesh Supply Chain: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.